Brazil’s health authorities authorized the first medical cannabis product registered under rules created in December 2019, marking an important milestone for the industry in Latin America’s largest economy.
The U.S. Food and Drug Administration is approving a growing number of applications from cannabis companies looking to conduct clinical trials studying medical marijuana. That development could lead to multiple cannabis-based medicines—including flower—receiving FDA approval to be commercialized and sold within the next five years.
MedMen Enterprises is undergoing a slow-motion restructuring of its capital structure and operations in public view as its lenders, led by Gotham Green Partners, equitized the company’s credit facility into something resembling preferred equity.
The president of the narcotics enforcement agency of the United Nations is questioning whether the agency’s decades-old drug conventions are outdated given global policy developments in recent years involving drugs such as cannabis.
Ellen Deutsch, a 20-year veteran of brand building in the food industry, offers her insights on how hemp and CBD companies will fare as new regulations are introduced to the market as well as commonalities she sees with the food industry.
A popular cannabis-derived epilepsy treatment is increasing sales for a London company making pharmaceutical treatments from marijuana.
Andrea Small-Howard has a unique view into how the medical side of the cannabis space is evolving.
She’s the chief science officer at GB Sciences, a Las Vegas-based marijuana company pursuing two strategies – one recreational, and the other aiming for U.S. Food and Drug Administration (FDA) approval of its medical cannabis products.
